Global self-care company Perrigo has launched SolpaOne®, its first maximum strength, 1000mg paracetamol in one effervescent tablet.
The product is the latest in the expansion of its Solpadeine® pain portfolio, the number one pharmacy brand in adult oral analgesics.
SolpaOne® provides a utilisable new brand for pharmacists to recommend as a convenient, gentle on the stomach over-the-counter solution for fast pain relief, getting to work up to two times faster than normal paracetamol tablets.
SolpaOne® is an ideal recommendation for those seeking pain relief guidance from their pharmacist for headaches, back pain, and everyday pain and fever associated with colds, flu and sore throats.
SolpaOne is a sodium conscious option for patients who may be on a low sodium diet or prefer effervescent or soluble formats.
Its convenient tablet form makes it an exemplary pain management essential from Solpadeine®, a trusted brand among HCPs and UK consumers. Whether it be stocked in the medicine cabinet, desk drawer, or travel bag for whenever pain strikes.
The launch of SolpaOne will be supported with a large scale media campaign, driving key messages such as pharmacy exclusivity, effectiveness and convenience.
Sander Moeyaert, marketing drector at Perrigo, said: “As the role of the community pharmacy sector continues to evolve and step-up to support the UK as a primary care service, pharmacists deserve over-the-counter products they can trust as a sound recommendation to support self-care. SolpaOne® will deliver in this space and along with its strong credentials in convenience and effectiveness, this new brand will allow support and reassure pharmacists and consumers alike.”
SolpaOne® joins a lineup of widely available Solpadeine® products that command strong consumer awareness and brand penetration within UK pharmacies, including Solpadeine Max and Solpadeine Plus.
Perrigo UK has listed a SolpaOne® RRP of £5.19.
